Study wrapper · #969
Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
Li C, Lin C, Cai X, et al. Obesity (Silver Spring, Md.). 2025.
DOI: 10.1002/oby.70054PubMed: 41189318
Editor's note
A meta-analysis of 25 RCTs (40,731 participants) examining whether antiobesity medications alter obesity-associated cancer risk. Tirzepatide and cagrilintide appear only within a coagonist subgroup that showed a borderline association, while overall medications showed no association. The peptide relevance is incidental to a broad drug-class question, so the subgroup signal should be read cautiously.
Plain-language abstract
This meta-analysis of 25 trials found antiobesity medications overall were not associated with reduced obesity-related cancer risk, though a coagonist subgroup including tirzepatide and cagrilintide showed a possible signal.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026